Intimation under regulation 30 of SEBI(LODR) regulations,2015-appointment of chief financial officer("CFO"), Key Managerial Personnel

Management Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹34.00

prior close

₹32.01

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-4.7% vs market

Pharmaceuticals peers, median of 153sector+0.6%-5.3% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7+0.0-4.7+0.6-5.3

Next day

-7.1-1.9-5.2-1.3-5.7

-5.1-3.6-1.6-2.8-2.4

-10.9-4.4-6.5-3.6-7.2

-7.9-4.1-3.9-3.8-4.1

-7.2-4.1-3.1-3.7-3.5

-7.6-5.8-1.9-5.1-2.6

15d

-9.7-6.3-3.4-8.0-1.7

-4.0-2.1-1.9-4.2+0.2

-11.8-12.3+0.5-10.9-0.8

-13.9-11.1-2.8-10.8-3.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kimia Biosciences Ltd has appointed Mr. Naveen Sharma as its new Chief Financial Officer and Key Managerial Personnel, effective January 7, 2026. The appointment was approved by the Board of Directors at a meeting held the same day. Mr. Sharma is a Chartered Accountant with over 18 years of experience spanning finance, accounting, governance, and strategic leadership across financial services, EPC, manufacturing, and banking sectors. The disclosure was filed under SEBI LODR Regulation 30, with further details provided in Annexure A.

Likely market impact

This is a routine KMP appointment with no immediate material impact on shareholders. Bringing in an experienced CFO with strong governance and compliance background may be viewed positively by investors focused on financial discipline and reporting quality.